Cognitive Genetics and Alzheimer’s Disease Mechanisms

The interplay between genetic variation and molecular pathology underlies individual susceptibility and progression of Alzheimer’s disease. Key risk alleles, most notably the apolipoprotein E ε4 variant, modulate the accumulation of amyloid-β peptides and hyperphosphorylated tau, driving synaptic dysfunction and neuronal loss. Beyond single-gene effects, polygenic risk scores have emerged to quantify cumulative genetic burden, while protective variants such as those in the KIBRA gene offer insight into mechanisms of cognitive resilience. Advances in high-throughput transcriptome profiling have uncovered novel gene signatures and dysregulated pathways—ranging from endocannabinoid signalling to vascular endothelial growth factor cascades—that contribute to neuronal vulnerability. Peripheral compartments, including the gut and blood, are now recognised as reservoirs for disease-related proteins and inflammatory mediators, opening avenues for non-invasive biomarker development. Together, these findings integrate genetic predisposition, protein aggregation, neuroinflammation and systemic factors into a coherent framework for understanding Alzheimer’s onset, progression and potential intervention points.

Research from Nature Portfolio

One foundational study has elucidated the interaction between the KIBRA gene polymorphism and APOE ε4 status in cognitively normal adults with elevated amyloid-β burden. Individuals carrying the KIBRA T allele exhibited slower rates of global cognitive decline and reduced hippocampal atrophy compared with non-carriers, despite equivalent amyloid accumulation. This work highlights a genetic resilience mechanism whereby KIBRA modulates synaptic plasticity pathways to counteract APOE-driven vulnerability, suggesting stratification of at-risk populations for targeted prevention strategies.

Cognitive Genetics and Alzheimer’s Disease Mechanisms publication trend

The graph below shows the total number of articles in cognitive genetics and alzheimer’s disease mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Amyloid-β (Aβ): Peptides derived from amyloid precursor protein that aggregate extracellularly to form plaques and trigger neurotoxicity.

Neurofibrillary tangles: Intracellular accumulations of hyperphosphorylated tau protein that disrupt microtubule stability and neuronal transport.

Apolipoprotein E ε4 (APOE ε4): A common genetic variant that increases risk for Alzheimer’s by promoting amyloid aggregation and impairing clearance.

KIBRA: A synaptic plasticity protein encoded by the WWC1 gene; T-allele carriers show preserved memory and reduced hippocampal atrophy in Alzheimer’s contexts.

Transcriptome profiling: High-throughput measurement of global gene expression levels used to identify pathways and biomarkers associated with disease.

Hippocampal atrophy: Reduction in hippocampal volume, reflecting loss of neurons and synapses critical for memory formation.

References

1. Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study. Alzheimer's Research & Therapy (2024).
2. Towards early detection of neurodegenerative diseases: A gut feeling. Frontiers in Cell and Developmental Biology (2023).
3. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports (2018).
4. Differential Transcriptome Profiling Unveils Novel Deregulated Gene Signatures Involved in Pathogenesis of Alzheimer’s Disease. Biomedicines (2022).